Development Stage and Anticipated Milestones Antibody Program TherapeuticIndication Lead Optimization IND Enabling Phase 1 Phase 2 Phase 3 ANB032(BTLA agonist) Atopic Dermatitis P2b initiated Q2 2023Top-line data YE 2024 Rosnilimab(PD-1 agonist) P2b initiated Q4 2023Top-line data H1 2026 ANB033(CD122 antagonist) Inflammatory Diseases Ulcerative Colitis Rheumatoid Arthritis IND Submission H1 2024 ANB101(BDCA2 modulator) Inflammatory Diseases IND Submission H2 2024 P2b initiated Q2 2023Top-line data mid 2025 Immune Cell Modulators Generalized PustularPsoriasis (GPP) GEMINI-1 and GEMINI-2 atmedical conf H2 2024GEMINI-1 BLA Q3 2024 Etokimab(IL-33 antagonist) Respiratory Disorders P2b/3-ready Out-license in 2024 No further internal investment Legacy Programs Available for Outlicensing Cytokine Antagonists Imsidolimab(IL-36R antagonist)